Home » Avant Sells $61 Million in Rights of Rotarix Sales
Avant Sells $61 Million in Rights of Rotarix Sales
Avant Immunotherapeutics will raise up to $61 million
by selling a stake in the net royalties it expects from a vaccine that helps
prevent severe diarrhea in young children. The Needham company said it entered
into an agreement with Paul Royalty Fund II LP, to sell up to a $61 million
in interest in the net royalties Avant expects from global sales of its Rotarix
vaccine. Avant will get $50 million from the deal over the next year.
Boston
Business Journal
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May